PEDRO
PÉREZ SEGURA
Profesor asociado de Ciencias de la Salud
Hospital General Universitario de Valencia
Valencia, EspañaPublicaciones en colaboración con investigadores/as de Hospital General Universitario de Valencia (10)
2022
-
SEOM clinical guidelines for the prophylaxis of infectious diseases in cancer patients (2021)
Clinical and Translational Oncology, Vol. 24, Núm. 4, pp. 724-732
2020
-
A phase II randomized, multicenter, open-label trial of continuing adjuvant temozolomide beyond 6 cycles in patients with glioblastoma (GEINO 14-01)
Neuro-oncology, Vol. 22, Núm. 12, pp. 1851-1861
2018
-
Delay in starting radiotherapy due to neoadjuvant therapy does not worsen survival in unresected glioblastoma patients
Clinical and Translational Oncology, Vol. 20, Núm. 12, pp. 1529-1537
2017
-
Peculiarities of the obese patient with cancer: a national consensus statement by the Spanish Society for the Study of Obesity and the Spanish Society of Medical Oncology
Clinical and Translational Oncology, Vol. 19, Núm. 6, pp. 682-694
2016
-
Bevacizumab and temozolomide versus temozolomide alone as neoadjuvant treatment in unresected glioblastoma: the GENOM 009 randomized phase II trial
Journal of Neuro-Oncology, Vol. 127, Núm. 3, pp. 569-579
2015
-
A phase II study of feasibility and toxicity of bevacizumab in combination with temozolomide in patients with recurrent glioblastoma
Clinical and Translational Oncology, Vol. 17, Núm. 9, pp. 743-750
-
Obesity as a risk factor in cancer: A national consensus of the Spanish Society for the Study of Obesity and the Spanish Society of Medical Oncology
Clinical and Translational Oncology, Vol. 17, Núm. 10, pp. 763-771
2014
2012
-
SEOM guideline for the treatment of malignant glioma
Clinical and Translational Oncology, Vol. 14, Núm. 7, pp. 545-550
2010
-
Extended-schedule dose-dense temozolomide in refractory gliomas
Journal of Neuro-Oncology, Vol. 96, Núm. 3, pp. 417-422